AU2015265916B2 - Pharmaceutical combinations for immunotherapy - Google Patents
Pharmaceutical combinations for immunotherapy Download PDFInfo
- Publication number
- AU2015265916B2 AU2015265916B2 AU2015265916A AU2015265916A AU2015265916B2 AU 2015265916 B2 AU2015265916 B2 AU 2015265916B2 AU 2015265916 A AU2015265916 A AU 2015265916A AU 2015265916 A AU2015265916 A AU 2015265916A AU 2015265916 B2 AU2015265916 B2 AU 2015265916B2
- Authority
- AU
- Australia
- Prior art keywords
- ntr
- pdcs
- cells
- disease
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000009169 immunotherapy Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 86
- 238000012360 testing method Methods 0.000 claims abstract description 73
- 239000000126 substance Substances 0.000 claims abstract description 68
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims abstract description 27
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims description 202
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 147
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 127
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 101
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 87
- 239000000556 agonist Substances 0.000 claims description 86
- 230000011664 signaling Effects 0.000 claims description 74
- 230000014509 gene expression Effects 0.000 claims description 66
- 102000004127 Cytokines Human genes 0.000 claims description 63
- 108090000695 Cytokines Proteins 0.000 claims description 63
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 239000005557 antagonist Substances 0.000 claims description 59
- 241000282414 Homo sapiens Species 0.000 claims description 58
- 241001465754 Metazoa Species 0.000 claims description 56
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 55
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 52
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 40
- 229960005486 vaccine Drugs 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 230000002829 reductive effect Effects 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 31
- 239000003446 ligand Substances 0.000 claims description 31
- 238000012216 screening Methods 0.000 claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 230000028327 secretion Effects 0.000 claims description 29
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 28
- 238000009739 binding Methods 0.000 claims description 28
- 208000024908 graft versus host disease Diseases 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 102000002689 Toll-like receptor Human genes 0.000 claims description 22
- 108020000411 Toll-like receptor Proteins 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 22
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 21
- 230000003993 interaction Effects 0.000 claims description 21
- 208000006673 asthma Diseases 0.000 claims description 20
- 238000003501 co-culture Methods 0.000 claims description 20
- 239000004055 small Interfering RNA Substances 0.000 claims description 20
- 230000000903 blocking effect Effects 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 18
- 238000010171 animal model Methods 0.000 claims description 18
- 230000001270 agonistic effect Effects 0.000 claims description 17
- 230000035755 proliferation Effects 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- OGIAAULPRXAQEV-UHFFFAOYSA-N odn 2216 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=O)C(OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 OGIAAULPRXAQEV-UHFFFAOYSA-N 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 15
- 102100033857 Neurotrophin-4 Human genes 0.000 claims description 14
- 230000003042 antagnostic effect Effects 0.000 claims description 14
- 150000003384 small molecules Chemical class 0.000 claims description 14
- 238000002054 transplantation Methods 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 13
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims description 13
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims description 13
- 201000009961 allergic asthma Diseases 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 201000006417 multiple sclerosis Diseases 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 11
- 101000743353 Homo sapiens Vacuolar protein sorting-associated protein 11 homolog Proteins 0.000 claims description 11
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 11
- 102100038309 Vacuolar protein sorting-associated protein 11 homolog Human genes 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 claims description 11
- 208000026935 allergic disease Diseases 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010006448 Bronchiolitis Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 206010039710 Scleroderma Diseases 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 244000045947 parasite Species 0.000 claims description 6
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 239000012646 vaccine adjuvant Substances 0.000 claims description 6
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 claims description 5
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 238000010195 expression analysis Methods 0.000 claims description 5
- 229960002751 imiquimod Drugs 0.000 claims description 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 229950010550 resiquimod Drugs 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 claims description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 229940124670 gardiquimod Drugs 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 4
- DHYWDEXXBWTTEH-UHFFFAOYSA-N odn 2007 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)C(O)C1 DHYWDEXXBWTTEH-UHFFFAOYSA-N 0.000 claims description 4
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 claims description 4
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 4
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 4
- SURCGQGDUADKBL-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(NCCO)C2=O)=O)=C3C2=CC=CC3=C1 SURCGQGDUADKBL-UHFFFAOYSA-N 0.000 claims description 3
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 208000031091 Amnestic disease Diseases 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010003253 Arthritis enteropathic Diseases 0.000 claims description 3
- 206010003267 Arthritis reactive Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 3
- 208000027496 Behcet disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000010392 Bone Fractures Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000027932 Collagen disease Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 108010040721 Flagellin Proteins 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 101000605088 Homo sapiens Ligand-dependent corepressor Proteins 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 102100038260 Ligand-dependent corepressor Human genes 0.000 claims description 3
- 208000028656 Löfgren syndrome Diseases 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 3
- 201000007737 Retinal degeneration Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 206010044688 Trisomy 21 Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000027207 Whipple disease Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 230000006986 amnesia Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- 230000003683 cardiac damage Effects 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 229950009370 fulranumab Drugs 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- 230000004068 intracellular signaling Effects 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229950005634 loxoribine Drugs 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- UIRLPEMNFBJPIT-UHFFFAOYSA-N odn 2395 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(O)=O)C(OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 UIRLPEMNFBJPIT-UHFFFAOYSA-N 0.000 claims description 3
- 210000001328 optic nerve Anatomy 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 208000032253 retinal ischemia Diseases 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000037804 stenosis Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 229950008160 tanezumab Drugs 0.000 claims description 3
- 239000000277 virosome Substances 0.000 claims description 3
- 208000009935 visceral pain Diseases 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 108020000946 Bacterial DNA Proteins 0.000 claims description 2
- 101710146739 Enterotoxin Proteins 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims description 2
- 150000001399 aluminium compounds Chemical class 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 229940077746 antacid containing aluminium compound Drugs 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 230000007783 downstream signaling Effects 0.000 claims description 2
- 239000000147 enterotoxin Substances 0.000 claims description 2
- 231100000655 enterotoxin Toxicity 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 7
- 102100036123 Far upstream element-binding protein 2 Human genes 0.000 claims 1
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000008105 immune reaction Effects 0.000 abstract description 8
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 229940053128 nerve growth factor Drugs 0.000 description 124
- 241000699670 Mus sp. Species 0.000 description 63
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 50
- 108010058846 Ovalbumin Proteins 0.000 description 50
- 230000028993 immune response Effects 0.000 description 49
- 229940092253 ovalbumin Drugs 0.000 description 48
- 102000005962 receptors Human genes 0.000 description 37
- 108020003175 receptors Proteins 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 230000001965 increasing effect Effects 0.000 description 35
- 241001529936 Murinae Species 0.000 description 31
- 230000004044 response Effects 0.000 description 30
- 230000000638 stimulation Effects 0.000 description 27
- 210000004443 dendritic cell Anatomy 0.000 description 26
- 230000001404 mediated effect Effects 0.000 description 21
- 102000004889 Interleukin-6 Human genes 0.000 description 20
- 108090001005 Interleukin-6 Proteins 0.000 description 20
- 230000006698 induction Effects 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 18
- 102000006992 Interferon-alpha Human genes 0.000 description 17
- 108010047761 Interferon-alpha Proteins 0.000 description 17
- 108010002616 Interleukin-5 Proteins 0.000 description 17
- 102100039897 Interleukin-5 Human genes 0.000 description 17
- 229940100602 interleukin-5 Drugs 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 229940100601 interleukin-6 Drugs 0.000 description 16
- 102000004388 Interleukin-4 Human genes 0.000 description 15
- 108090000978 Interleukin-4 Proteins 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 210000003289 regulatory T cell Anatomy 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 14
- 210000002443 helper t lymphocyte Anatomy 0.000 description 14
- 229940028885 interleukin-4 Drugs 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 230000001575 pathological effect Effects 0.000 description 14
- 230000001629 suppression Effects 0.000 description 14
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 210000003979 eosinophil Anatomy 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 12
- 102000000588 Interleukin-2 Human genes 0.000 description 12
- -1 aluminium oxyhydroxide Chemical compound 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 11
- 102000004230 Neurotrophin 3 Human genes 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 108091008874 T cell receptors Proteins 0.000 description 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
- 239000013566 allergen Substances 0.000 description 11
- 239000012131 assay buffer Substances 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 229940032018 neurotrophin 3 Drugs 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 10
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 10
- 102000003816 Interleukin-13 Human genes 0.000 description 10
- 108090000176 Interleukin-13 Proteins 0.000 description 10
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 201000002491 encephalomyelitis Diseases 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000029069 type 2 immune response Effects 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 239000012190 activator Substances 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000011534 wash buffer Substances 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 8
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- 230000006052 T cell proliferation Effects 0.000 description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 159000000013 aluminium salts Chemical class 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 5
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 5
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 5
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 5
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 5
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 208000026278 immune system disease Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000011325 microbead Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 102000005309 phosducin Human genes 0.000 description 5
- 108010031256 phosducin Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000002175 goblet cell Anatomy 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000003843 mucus production Effects 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 3
- 102100034980 ICOS ligand Human genes 0.000 description 3
- 108091054729 IRF family Proteins 0.000 description 3
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 3
- 102100028762 Neuropilin-1 Human genes 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 108050000808 TNF receptor-associated factor TRAF Proteins 0.000 description 3
- 102000008889 TNF receptor-associated factor TRAF Human genes 0.000 description 3
- 102000018594 Tumour necrosis factor Human genes 0.000 description 3
- 108050007852 Tumour necrosis factor Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000010085 airway hyperresponsiveness Effects 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000005735 apoptotic response Effects 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229940056360 penicillin g Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 102100036465 Autoimmune regulator Human genes 0.000 description 2
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229940124957 Cervarix Drugs 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 2
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 101100260758 Mus musculus Tlr9 gene Proteins 0.000 description 2
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 2
- 101710090077 NF-kappa-B essential modulator Proteins 0.000 description 2
- 101150061038 NLRP3 gene Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102000000160 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Human genes 0.000 description 2
- 108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000011488 interferon-alpha production Effects 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- IJQVBLGOXGPMMZ-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(=O)NCCCN(C)C IJQVBLGOXGPMMZ-UHFFFAOYSA-N 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000012121 regulation of immune response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108010064884 trkA Receptor Proteins 0.000 description 2
- 102000015533 trkA Receptor Human genes 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- ZKKBWNOSVZIFNJ-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;diphosphono hydrogen phosphate Chemical compound O=C1NC(N)=NC2=C1NC=N2.OP(O)(=O)OP(O)(=O)OP(O)(O)=O ZKKBWNOSVZIFNJ-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- WOPPMMSRGOPMJF-UHFFFAOYSA-N 4-[2-[3-[4-chloro-3-(trifluoromethyl)phenyl]-2,5-dihydropyrrol-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC(=CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)CC1 WOPPMMSRGOPMJF-UHFFFAOYSA-N 0.000 description 1
- WHLJMRULFSSZII-UHFFFAOYSA-N 4-[2-[4-(2,3-dichlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C(=C(Cl)C=CC=2)Cl)CC1 WHLJMRULFSSZII-UHFFFAOYSA-N 0.000 description 1
- OJGSEOTWCMZAHR-UHFFFAOYSA-N 4-[2-[4-(3-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C=C(Cl)C=CC=2)CC1 OJGSEOTWCMZAHR-UHFFFAOYSA-N 0.000 description 1
- IUNGIGJLVDXDDV-UHFFFAOYSA-N 4-[2-[4-(3-methylphenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound CC1=CC=CC(C=2CCN(CC=2)C(=O)CN2CC(=O)N(CC2)C=2N=CC(=CC=2)C(F)(F)F)=C1 IUNGIGJLVDXDDV-UHFFFAOYSA-N 0.000 description 1
- VSHLTEPHAMSCRR-UHFFFAOYSA-N 4-[2-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-(6-chloropyridin-2-yl)piperazin-2-one Chemical compound C1=CC(Cl)=CC=C1C1=CCN(C(=O)CN2CC(=O)N(CC2)C=2N=C(Cl)C=CC=2)CC1 VSHLTEPHAMSCRR-UHFFFAOYSA-N 0.000 description 1
- QWBGTTHCZYHXNO-UHFFFAOYSA-N 4-[2-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C=CC(Cl)=CC=2)CC1 QWBGTTHCZYHXNO-UHFFFAOYSA-N 0.000 description 1
- WJNNAFBKEQFCET-UHFFFAOYSA-N 4-[2-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-pyridin-2-ylpiperazin-2-one Chemical compound C1=CC(Cl)=CC=C1C1=CCN(C(=O)CN2CC(=O)N(CC2)C=2N=CC=CC=2)CC1 WJNNAFBKEQFCET-UHFFFAOYSA-N 0.000 description 1
- QHBMMWRVCZYFLO-UHFFFAOYSA-N 4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 QHBMMWRVCZYFLO-UHFFFAOYSA-N 0.000 description 1
- ISURFUYIOSOQGU-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-(5-methylpyridin-2-yl)piperazin-2-one Chemical compound N1=CC(C)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)CC1 ISURFUYIOSOQGU-UHFFFAOYSA-N 0.000 description 1
- UYNCUTYQPHQBIH-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)CC1 UYNCUTYQPHQBIH-UHFFFAOYSA-N 0.000 description 1
- PGOJFFZQEHTMIP-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-pyridin-2-ylpiperazin-2-one Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(C=2CCN(CC=2)C(=O)CN2CC(=O)N(CC2)C=2N=CC=CC=2)=C1 PGOJFFZQEHTMIP-UHFFFAOYSA-N 0.000 description 1
- ILLICYXAZDPAKH-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-pyridin-3-ylpiperazin-2-one Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(C=2CCN(CC=2)C(=O)CN2CC(=O)N(CC2)C=2C=NC=CC=2)=C1 ILLICYXAZDPAKH-UHFFFAOYSA-N 0.000 description 1
- GNNFVSFMZIKJFM-UHFFFAOYSA-N 4-[2-[5-(2,3-dichlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC(=CCC2)C=2C(=C(Cl)C=CC=2)Cl)CC1 GNNFVSFMZIKJFM-UHFFFAOYSA-N 0.000 description 1
- HFLJZBIWQIYQIV-UHFFFAOYSA-N 4-[2-[5-(3-methoxyphenyl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound COC1=CC=CC(C=2CN(CCC=2)C(=O)CN2CC(=O)N(CC2)C=2N=CC(=CC=2)C(F)(F)F)=C1 HFLJZBIWQIYQIV-UHFFFAOYSA-N 0.000 description 1
- IIJFQMIESAUXIX-UHFFFAOYSA-N 4-[2-oxo-2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C=CC=CC=2)CC1 IIJFQMIESAUXIX-UHFFFAOYSA-N 0.000 description 1
- GYACDMABVLJLNC-UHFFFAOYSA-N 4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]ethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC=C(CC2)C=2C=C(C=CC=2)C(F)(F)F)CC1 GYACDMABVLJLNC-UHFFFAOYSA-N 0.000 description 1
- PVENPGLHUBKUKK-UHFFFAOYSA-N 4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]ethyl]-1-pyridin-2-ylpiperazin-2-one Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CC=2)C(=O)CN2CC(=O)N(CC2)C=2N=CC=CC=2)=C1 PVENPGLHUBKUKK-UHFFFAOYSA-N 0.000 description 1
- BHUOGNBXHXIPSZ-UHFFFAOYSA-N 4-[2-oxo-2-[4-[4-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]ethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CCN(C(=O)CN2CC(=O)N(CC2)C=2N=CC(=CC=2)C(F)(F)F)CC1 BHUOGNBXHXIPSZ-UHFFFAOYSA-N 0.000 description 1
- CQOUQWDHQJZARG-UHFFFAOYSA-N 4-[2-oxo-2-[5-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]ethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C(=O)CN(CC(=O)N2CC(=CCC2)C=2C=C(C=CC=2)C(F)(F)F)CC1 CQOUQWDHQJZARG-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108091011189 Caspase recruitment domains Proteins 0.000 description 1
- 102000021350 Caspase recruitment domains Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 101100449439 Drosophila melanogaster grass gene Proteins 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 101710091869 High affinity nerve growth factor receptor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 101000800479 Homo sapiens Toll-like receptor 9 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000039996 IL-1 family Human genes 0.000 description 1
- 108091069196 IL-1 family Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 108010029973 Lymphocytic choriomeningitis virus glycoprotein peptide Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 101100077710 Rattus norvegicus Mog gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 101710180188 T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- UPAZUDUZKTYFBG-HNPUZVNISA-N azane [(2S,3R,4R,5S,6R)-2,5-dihydroxy-6-[[(2R,3R,4R,5S,6R)-6-(hydroxymethyl)-5-phosphonooxy-3-[[(3R)-3-tetradecanoyloxytetradecanoyl]amino]-4-[(3R)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3-[[(3R)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3R)-3-hydroxytetradecanoate Chemical compound [NH4+].CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]2O)O[C@H](CO)[C@@H](OP(O)([O-])=O)[C@@H]1OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC UPAZUDUZKTYFBG-HNPUZVNISA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical class C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005208 blood dendritic cell Anatomy 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 238000003568 cytokine secretion assay Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 102000045710 human TLR9 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010037248 lantibiotic Pep5 Proteins 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 230000008779 noncanonical pathway Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000007076 release of cytoplasmic sequestered NF-kappaB Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14170362.9A EP2950095B1 (de) | 2014-05-28 | 2014-05-28 | Zellenbasierte Test- und Screeningverfahren auf Modulatoren von p75NTR-Signalisierung |
EP14170362.9 | 2014-05-28 | ||
PCT/EP2015/061851 WO2015181298A1 (en) | 2014-05-28 | 2015-05-28 | Pharmaceutical combinations for immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2015265916A1 AU2015265916A1 (en) | 2016-12-22 |
AU2015265916B2 true AU2015265916B2 (en) | 2021-07-29 |
Family
ID=50884248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015265916A Ceased AU2015265916B2 (en) | 2014-05-28 | 2015-05-28 | Pharmaceutical combinations for immunotherapy |
Country Status (7)
Country | Link |
---|---|
US (2) | US20170189522A1 (de) |
EP (1) | EP2950095B1 (de) |
JP (2) | JP6720147B2 (de) |
AU (1) | AU2015265916B2 (de) |
CA (1) | CA2949885A1 (de) |
ES (1) | ES2699410T3 (de) |
WO (1) | WO2015181298A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10760054B2 (en) * | 2014-12-29 | 2020-09-01 | Restem Llc | Natural killer cells and methods for enhancing viability, proliferation and cytotoxicity of same following cryopreservation |
US11249081B2 (en) | 2016-08-31 | 2022-02-15 | Agency For Science, Technology And Research | Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof |
CN106614260B (zh) * | 2016-09-06 | 2019-11-08 | 广东省人民医院 | 一种C5aR基因敲除小鼠cGVHD模型的建立方法 |
CN110234401B (zh) | 2016-11-09 | 2024-03-01 | 德克萨斯大学系统董事会 | 用于适应性免疫调节的方法和组合物 |
US20190336535A1 (en) | 2017-01-17 | 2019-11-07 | Tufts Medical Center, Inc. | Adoptive transfer of plasmacytoid dendritic cells to prevent or treat ocular diseases and conditions |
CN108728444A (zh) * | 2017-04-18 | 2018-11-02 | 长春华普生物技术股份有限公司 | 免疫调节性多核苷酸及其应用 |
US20220362292A1 (en) * | 2019-07-26 | 2022-11-17 | Tufts Medical Center, Inc. | Adoptive transfer of plasmacytoid dendritic cells to prevent or treat hair loss |
GB202014920D0 (en) * | 2020-09-22 | 2020-11-04 | Unikum Therapeutics Aps | Methods for treating cancer and autoimmune and inflammatory diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100029585A1 (en) * | 2008-08-01 | 2010-02-04 | Howbert J Jeffry | Toll-like receptor agonist formulations and their use |
WO2012101664A1 (en) * | 2011-01-24 | 2012-08-02 | Ospedale Pediatrico Bambino Gesu´ | Use of at least one p75ntr receptor inhibitor, alone or in association with at least one trka receptor activator, or of at least one trka receptor activator, for the treatment of chronic inflammatory diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0890105B1 (de) * | 1996-03-29 | 2006-11-22 | The Trustees Of Boston University | Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden |
DK0994721T3 (da) * | 1997-05-01 | 2007-04-02 | Protechtion Unltd Inc | Nervevækstfaktor som vaccineadjuvans |
IL139574A0 (en) * | 1998-05-18 | 2002-02-10 | Applied Research Systems | TNF-RII (p75) AGONISTS FOR TREATING ASTHMA AND OTHER ALLERGIC CONDITIONS |
JP2006519020A (ja) * | 2003-02-27 | 2006-08-24 | スリーエム イノベイティブ プロパティズ カンパニー | Tlr介在生物活性の選択的調節 |
CA2571130C (en) * | 2004-07-14 | 2014-08-19 | Janssen Pharmaceutica N.V. | P75ntr screening assay for indentifying modulators of apoptosis |
FR2932481B1 (fr) | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique. |
GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
MX340233B (es) * | 2010-08-31 | 2016-07-01 | Bionure Farma S L | Agonistas de receptores de neurotrofina y sus usos como medicamentos. |
-
2014
- 2014-05-28 EP EP14170362.9A patent/EP2950095B1/de not_active Not-in-force
- 2014-05-28 ES ES14170362T patent/ES2699410T3/es active Active
-
2015
- 2015-05-28 CA CA2949885A patent/CA2949885A1/en not_active Abandoned
- 2015-05-28 JP JP2017514961A patent/JP6720147B2/ja not_active Expired - Fee Related
- 2015-05-28 AU AU2015265916A patent/AU2015265916B2/en not_active Ceased
- 2015-05-28 WO PCT/EP2015/061851 patent/WO2015181298A1/en active Application Filing
- 2015-05-28 US US15/313,687 patent/US20170189522A1/en not_active Abandoned
-
2019
- 2019-04-24 US US16/393,214 patent/US20190381169A1/en not_active Abandoned
- 2019-06-10 JP JP2019107623A patent/JP6876746B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100029585A1 (en) * | 2008-08-01 | 2010-02-04 | Howbert J Jeffry | Toll-like receptor agonist formulations and their use |
WO2012101664A1 (en) * | 2011-01-24 | 2012-08-02 | Ospedale Pediatrico Bambino Gesu´ | Use of at least one p75ntr receptor inhibitor, alone or in association with at least one trka receptor activator, or of at least one trka receptor activator, for the treatment of chronic inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
AU2015265916A1 (en) | 2016-12-22 |
ES2699410T3 (es) | 2019-02-11 |
WO2015181298A1 (en) | 2015-12-03 |
JP2017525751A (ja) | 2017-09-07 |
CA2949885A1 (en) | 2015-12-03 |
US20170189522A1 (en) | 2017-07-06 |
JP6876746B2 (ja) | 2021-05-26 |
EP2950095B1 (de) | 2018-08-29 |
EP2950095A1 (de) | 2015-12-02 |
JP6720147B2 (ja) | 2020-07-15 |
JP2019178148A (ja) | 2019-10-17 |
US20190381169A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015265916B2 (en) | Pharmaceutical combinations for immunotherapy | |
US10577586B2 (en) | Compositions and methods for modulating an immune response | |
US20190233496A1 (en) | Chimeric receptors and methods of use thereof | |
AU2019215110A1 (en) | Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates | |
US20130195919A1 (en) | Induced dendritic cell compositions and uses thereof | |
KR20220045930A (ko) | 조작된 키메라 융합 단백질 조성물 및 이의 사용 방법 | |
WO2006023791A2 (en) | Methods and compositions for treating allergic inflammation | |
CN103370076A (zh) | 治疗毛发脱落疾病的方法 | |
WO2012040101A1 (en) | Compositions and methods for inducing migration by dendritic cells and an immune response | |
KR20070007291A (ko) | 면역 반응을 유도하거나 조절하는 방법 | |
KR102025417B1 (ko) | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2004024075A2 (en) | Chemokine receptor antagonists as therapeutic agents | |
KR102530161B1 (ko) | 제대혈 혈장 유래의 엑소좀 또는 이의 모방체 및 이의 면역억제 용도 | |
Talker et al. | Transcriptomic signature and metabolic programming of bovine classical and nonclassical monocytes indicate distinct functional specializations | |
EP1367393A1 (de) | Verfahren zur Verwendung des CD 163 Wegs zur Modulation einer Immunantwort | |
TWI841576B (zh) | 用於治療傳染病之共受體系統 | |
Ganguly | Activation and Functions of Plasmacytoid Dendritic Cells | |
Danielli | CALHM6: Function in the innate immune system and role in infectious diseases | |
Horuluoğlu | TLR agonists on autoimmunity, cancer and M1/M2 macrophage polarization | |
Sala | Caratterizzazione dei determinanti della differenziazione delle TH1 e TFH in seguito a infezioni virali: il ruolo dell'IFN-γ | |
Wurzenberger | Dendritic cell vaccines in tumor immunotherapy: Immune activation strategies with ligands for the Toll-like receptors 7 and 9 | |
Simkins | Immune Responses in Perforin Deficient Mice | |
Menzel | Role of the cell adhesion molecule L1 during neuroinflammation in the central nervous system | |
Wurzenberger | Dendritic cell vaccines in tumor immunotherapy | |
Ngoi | The opposing immunological effects of double-stranded RNA on cytotoxic CD8 T cell response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |